Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 144,756 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 144,756 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88. Following the transaction, the insider directly owned 18,630,739 shares in the company, valued at $679,649,358.72. This trade represents a 0.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The shares were sold at an average price of $37.17, for a total value of $6,426,655.83.
• On Thursday, August 20th, Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock. The stock was sold at an average price of $37.30, for a total value of $653,458.70.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV traded down $0.54 during midday trading on Friday, hitting $36.30. 6,185,493 shares of the stock traded hands, compared to its average volume of 5,631,176. Roivant Sciences Ltd. has a one year low of $11.60 and a one year high of $37.97. The business has a 50 day moving average price of $34.61 and a two-hundred day moving average price of $30.43. The company has a market cap of $26.22 billion, a PE ratio of -68.49 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.06 million. As a group, equities research analysts forecast that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Hedge Funds Weigh In On Roivant Sciences

Several large investors have recently bought and sold shares of ROIV. UBS Group AG boosted its holdings in Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after acquiring an additional 15,645,836 shares during the last quarter. Morgan Stanley grew its stake in shares of Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after acquiring an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after purchasing an additional 8,621,567 shares during the last quarter. Norges Bank purchased a new stake in shares of Roivant Sciences in the fourth quarter valued at about $112,750,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Roivant Sciences in the fourth quarter valued at about $76,272,000. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ROIV has been the subject of a number of analyst reports. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Thursday, August 6th. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Guggenheim lifted their price target on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Citigroup boosted their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.